Last reviewed · How we verify
TNF Inhibitor (tnf-inhibitor)
TNF Inhibitor (generic name: tnf-inhibitor) is a Monoclonal Antibody Small molecule drug developed by Pfizer. It is currently FDA-approved for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.
TNF Inhibitors are medications used to treat conditions such as Crohn's Disease, Polyarticular Course Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, and complications following a lung transplant. They work by inhibiting the action of Tumor Necrosis Factor, a protein involved in inflammation.
At a glance
| Generic name | tnf-inhibitor |
|---|---|
| Sponsor | Pfizer |
| Drug class | Monoclonal Antibody |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Ulcerative Colitis
- Crohn's Disease
- Plaque Psoriasis
- Juvenile Idiopathic Arthritis
- Axial Spondyloarthritis
- Psoriatic Arthritis with Distal Interphalangeal Involvement
- Moderate to Severe Ulcerative Colitis
- Non-Radiographic Axial Spondyloarthritis
- Moderate to Severe Plaque Psoriasis
- Active Ankylosing Spondylitis
- Moderate to Severe Crohn's Disease
- Moderate to Severe Rheumatoid Arthritis
- Active Psoriatic Arthritis
- Moderate to Severe Juvenile Idiopathic Arthritis
- Active Ulcerative Colitis
- Active Crohn's Disease
- Active Plaque Psoriasis
Common side effects
- Upper respiratory tract infection
- Bronchitis
- Urinary tract infection
- Rheumatoid arthritis
- Fall
- Herpes zoster
- Nasopharyngitis
- Hypertension
- Arthralgia
- Lymphopenia
- Back pain
- Diarrhoea
Drug interactions
- Abatacept
- Anakinra
- Azathioprine
- Cyclophosphamide
- Cyclosporine
- Glatiramer
- Hydroxychloroquine
- Immunosuppressants
- Live vaccines
- Methotrexate
- Mycophenolate
- Rituximab
Key clinical trials
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
- Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study
- Lumbar Spinal Fibrosis and TNF Alpha Inhibition (PHASE3)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNF Inhibitor CI brief — competitive landscape report
- TNF Inhibitor updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about TNF Inhibitor
What is TNF Inhibitor?
What is TNF Inhibitor used for?
Who makes TNF Inhibitor?
What is the generic name of TNF Inhibitor?
What drug class is TNF Inhibitor in?
What development phase is TNF Inhibitor in?
What are the side effects of TNF Inhibitor?
What does TNF Inhibitor target?
Related
- Drug class: All Monoclonal Antibody drugs
- Target: All drugs targeting TNF-alpha
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid Arthritis
- Indication: Drugs for Psoriatic Arthritis
- Indication: Drugs for Ankylosing Spondylitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing